CA
NZ
UK
AU
IND
US
Schwartz's confirmation as director of the CDC marks a critical turnover in public health leadership, with potential ramifications for the healthcare sector. The Senate's decision follows intense debate regarding Schwartz's capability to navigate contentious health policy issues and the ongoing conflict concerning health authority …
CytomX Therapeutics (NASDAQ: CTMX) reported earnings that fell short of consensus expectations, posting an earnings miss while revenue shrank dramatically to $1.4 million from $18.7 million a year earlier. The company’s cash balance stands at $330.3 million, not counting a recent $37.0 million payment …
Doximity, Inc. (NYSE: DOCS) reported revenues totaling $156.6 million for the first quarter ending June 30, reflecting a 7% year-over-year increase, albeit slightly below the $0.31 consensus EPS estimate with a reported EPS of $0.29. This discrepancy highlights the market's cautious outlook regarding the …
FIGS, Inc. (NYSE: FIGS) delivered earnings of $0.11 per share for the quarter ended June 30, well above the $0.07 consensus, and simultaneously announced a $100 million boost to its share repurchase program, raising the ceiling to $200 million. Net revenues surged 28.8% to …
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) reported earnings per share of $‑0.84 for the quarter ended June 30, 2026, beating the consensus forecast of $‑1.02.
Artivion, Inc. (NYSE: AORT) reported a strong revenue figure of $125.8 million for Q2 2026, marking an 11% increase from $113.0 million in the same quarter of 2025. This outperformance highlights Artivion's ability to exceed analysts' expectations, as reflected by a comparative anchor showing …
Caring Brands, Inc. (NASDAQ: CABR) announced it now holds five U.S. patents that protect its innovative Hair Enzyme Booster and Photocil platforms, which target a combined market opportunity exceeding $20 billion. This news comes at a time when shares are up 61% year-to-date, emphasizing …
The beat reflects progress in commercializing MYQORZO and the infusion of capital from a recent equity offering, both of which are key to the company’s near‑term financial trajectory.
This slight earnings shortfall occurred as the biopharmaceutical company marked its first full quarter of commercial sales for AVLAYAH (tividenofusp alfa-eknm), generating $3.6 million in net product revenue for the Hunter syndrome treatment. This initial AVLAYAH revenue, coupled with strategic financial moves, positions Denali …
Share price moved modestly higher, reflecting market optimism about the upcoming readouts.
Please wait processing your request...